JPRN-C000000184
Completed
Phase 2
Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutations - Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutations
Hokkaido Lung Cancer Clinical Study Group0 sites16 target enrollmentSeptember 12, 2005
Conditionsnon-small cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer
- Sponsor
- Hokkaido Lung Cancer Clinical Study Group
- Enrollment
- 16
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Serious concomitant systemic disorders 2\.Uncontrollable angina, acute myocardial infarction or severe heart failure within 3 months 3\.Uncontrollable diabetes mellitus or hypertension 4\.Active infection 5\.Interstitial pneumonia 6\.Uncontrollable pleural effusion 7\.Active ulcer 8\.Active second malignancy 9\.History of severe hypersensitivity 10\.Severe SVC syndrome 11\.Pregnancy 12\.Other severe complication
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Not Applicable
PhaseII stady of gefitinib and in patients with relapsed advanced non-small cell lung cancerJPRN-C000000142Department of Medical Oncology Kinki University School of Medicine30
Completed
Phase 2
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33
Completed
Not Applicable
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
Completed
Phase 2
A phase II study of first-line gefitinib for advanced and recurrent EGFR mutation positivenon-small cell lung cancerwith high-risk factorsnon-small cell lung cancerJPRN-UMIN000004822Kanagawa Cancer Center37
Completed
Not Applicable
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutationslung adenocarcinomaJPRN-UMIN000002783agano lung cancer study meeting15